Kallyope Stock

kallyope.comHealthcareFounded: 2015Funding to Date: $479.46MM

Kallyope is a platform biotechnology company dedicated to unlocking the therapeutic potential of the gut-brain axis by integrating cutting-edge technologies in sequencing, computational biology, neural imaging, cellular and molecular biology, and human genetics to provide an understanding of gut-brain biology that will lead to transformational therapeutics that improve human health.

Register for Details

For more details on financing and valuation for Kallyope, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

Enterprise Value (based on primary financings)

Powered by Forge Data
Enterprise Value

View Enterprise Value for Kallyope.

Register Today


Management Team

Juha Lauren Ph.D
Chief Business Officer
Maximilian Lombardo
Senior Data Research Associate
Tom Maniatis Ph.D
Co-Founder & Board Member
Charles Zuker Ph.D
Ann Weber Ph.D
Senior Vice President - Drug Discovery
Brett Lauring
Chief Medical Officer
Nancy Thornberry
Chief Executive Officer & Board Member
Richard Axel MD
Robert Anstey
Vice President, Business Development

Board Members

Joshua Wolfe
Lux Capital Management
Tony Evnin Ph.D
Amy Schulman JD
Polaris Partners
Timothy Kutzkey Ph.D
The Column Group
William Rieflin JD
Nancy Thornberry
Terry McGuire
Tom Maniatis Ph.D

Other companies like Kallyope in the Healthcare sector

Last Round Est. Valuation
Last Round Est. Valuation
Last Round Est. Valuation
Last Round Est. Valuation
Last Round Est. Valuation


Kallyope, a biotech company focused on identifying therapeutic opportunities involving the gut-brain axis, raised $21m in Series B financing